Financial toxicity as logistical and relational burden across the lifespan during autologous transplant preparation - Report - DentalSpire

Financial toxicity as logistical and relational burden across the lifespan during autologous transplant preparation

  • By

  • Sean N. Halpin

  • April 30, 2026

  • 0 min

Share

Clinical Report: The Impact of Financial Toxicity on ASCT Preparation

Overview

This study explores the indirect expressions of financial toxicity faced by patients preparing for autologous stem cell transplant (ASCT) for multiple myeloma. Findings indicate that financial strain significantly influences treatment readiness and decision-making, highlighting the necessity for proactive financial navigation.

Background

Financial toxicity is a critical issue in cancer care, particularly affecting patients with hematologic malignancies like multiple myeloma. The burden of treatment costs can lead to adverse psychosocial outcomes and decreased quality of life. Understanding how financial toxicity manifests during ASCT preparation is essential for improving patient support and care.

Data Highlights

No numerical data presented in the article.

Key Findings

  • Financial toxicity often emerges indirectly through work disruption and caregiver burdens.
  • Patients frequently minimize discussions about financial concerns, prioritizing medical necessity over costs.
  • Caregivers absorb significant unpaid labor, exacerbating household financial strain.
  • Nearly half of patients undergoing ASCT experience meaningful financial hardship.
  • Financial strain is linked to worse health-related quality of life and mental health outcomes.

Clinical Implications

Healthcare providers should recognize the relational and logistical challenges posed by financial toxicity in ASCT preparation. Proactive financial navigation strategies are essential to support patients and their families in managing these burdens effectively.

Conclusion

Highlight the importance of qualitative research in understanding financial toxicity.

References

  1. Author(s)/Org, Source, Year -- Title
  2. Author(s)/Org, Source, Year -- Title
  3. Author(s)/Org, Source, Year -- Title
  4. Author(s)/Org, Source, Year -- Title
  5. Author(s)/Org, Source, Year -- Title
  6. Author(s)/Org, Source, Year -- Title
  7. Author(s)/Org, Source, Year -- Title
  8. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations | Bone Marrow Transplantation
  9. Autologous Stem Cell Transplant: A Guide for Patients & Caregivers | Memorial Sloan Kettering Cancer Center
  10. NCCN GuidelinesĀ® Insights - Distress Management, Version 1.2026 | NCCN Continuing Education

Original Source(s)

Related Content